Benign Prostatic Hyperplasia

Jennifer A. Robles, MD, MPH, outlines 3 key factors that may be preventing more widespread adoption of HoLEP across the US.

Jennifer A. Robles, MD, MPH, highlights potential factors contributing to the surge in HoLEP utilization across the US.

Jennifer A. Robles, MD, MPH, discusses a study assessing trends and geographic disparities in HoLEP utilization across the United States.

Bansal unpacks how to personalize treatment plans in a therapeutic landscape now filled with minimally invasive and surgical options.

However, M-HoLEP was superior in terms of enucleation time and efficiency, catheterization time, and hospital stay.

According to the authors, these data support Rezūm as an alternative first-line treatment option for patients at risk of BPH progression.

One consideration is the setting in which the procedure is performed.

Bilal I. Chughtai, MD, walks through the design and potential implications of a pivotal trial of the Butterfly Prostatic Device.

Here’s a look back at notable news between April and June 2025.

A recap of the FDA submissions and regulatory decisions in urology from June 2025.

McVary's expectation is that the results will be sustainable because the short-term outcomes for larger prostates appear superimposable on the longer-term outcomes for smaller, previously restricted prostate volumes

The system is now cleared for use in prostates up to 150 cm3.

Amy E. Krambeck, MD, discusses how to define success and how to determine the optimal timing for adding on a new partner.

The approval is supported by several studies highlighting the efficacy of Rezūm Water Vapor Therapy in patients with larger prostates.

MIST utilization increased from 7% in 2015 to 51% in 2022 among men aged 50 to 54.

“We have definitely seen a shift in the idea of being able to really tailor treatments to both the individual and terms of what is important to them with values and preferences, as well as their individual prostate,” says Dean Elterman, MD, MSc.

Further follow-up and additional treatments in the study are ongoing.

“We're now entering an era of new types of technologies to treat BPH in a minimally invasive fashion,” says Dean Elterman, MD.

Panelist discusses how urologists can benefit from adopting newer treatment modalities like aqua ablation for BPH, emphasizing its growing popularity, ease of learning, and efficiency in improving patient throughput, while still allowing urologists to leverage their existing skills.

James C. Ulchaker, MD, shares his insights on the current range of BPH therapies.

Panelist discusses how hospitals benefit from adopting aqua ablation therapy by improving surgical efficiency, reducing turnover times, enabling outpatient procedures, and providing a highly effective treatment option that can enhance patient outcomes while preserving sexual function.

Panelist discusses how the ability to administer treatments robotically, regardless of prostate size, affects resource expenditures in a clinic, highlighting the need for extended recovery periods and increased use of apps to streamline patient management and reduce resource burdens.

Urologist Garrett D. Pohlman, MD, reflects on the benign prostatic hyperplasia offerings from the 2025 American Urological Association Annual Meeting.

Amy E. Krambeck, MD, recaps her talk from AUA 2025.

Panelist discusses how benign prostatic hyperplasia (BPH) and its treatments impact men’s sexual health, emphasizing the importance of balancing symptom relief with sexual function preservation, and how patient concerns, along with treatment advancements like aqua ablation, have simplified decision-making in clinical practice.